臨床試験を検索：Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in prami
合計1件
-
First Affiliated Hospital of Zhejiang UniversityHongguan biological pharmaceutical co.終了しました
このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。
スポンサーと協力者
- Biorobotic Institute Scuola Superiore sant'Anna Pisa
- Genuv Inc.
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
- Marcus Vinícius Guimarães de Lacerda
- Hoersholm Hospital
- Egyptian Russian University
- Van Boven, Robert W., M.D.
- Royal Hobart Hospital Research Foundation (funding source)
- Pancreatic Cancer UK
- The People's Hospital of Guangxi Zhang Autonomous Region
- Kuwait University
- Liming Cheng
- Xiao-Ming Mao
- Friedrich Miescher Institute for Biomedical Research (FMI)
- Kerstyn C. Zalesin, M.D.
- Only For Children Pharmaceuticals
- Jia Liu
- Hopeful Aging
- Klinikum Bad Woerishofen
- Sahar Salehi
- 全リストを表示
CROs by country
- Contract Research Organizations in Australia
- Contract Research Organizations in Bangladesh
- Contract Research Organizations in Cote d'Ivoire
- Contract Research Organizations in Finland
- Contract Research Organizations in Guinea
- Contract Research Organizations in Indonesia
- Contract Research Organizations in Kyrgyzstan
- Contract Research Organizations in Luxembourg
- Contract Research Organizations in Montenegro
- Contract Research Organizations in Mozambique
- Contract Research Organizations in Paraguay
- Contract Research Organizations in Slovenia
- Contract Research Organizations in South Korea
- CRO list by country